Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Reports A "Solid" Third Quarter, But Expects Further EU Pricing Pressure

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche's sales grew only 2% in the first nine months of 2010, held back by U.S. health care reform and EU price cuts, a decline in Tamiflu sales and adverse currency fluctuations.

You may also be interested in...



Avastin Down, But Not Out Yet In Metastatic Breast Cancer Indication

FDA's decision to withdraw approval of Roche/Genentech's Avastin for first-line metastatic breast cancer is proving to be an unpopular action, though the ramifications are not yet clear.

Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071308

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel